Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Mirvetuximab Soravtansine Metastatic Neoplasm	Eli Lilly and Company	P3	CCC (54)
Mirvetuximab Soravtansine Ovarian Neoplasm	Eli Lilly and Company	P3	CCC (54)
rc48-adc Gastroesophageal Adenocarcinoma	Jazz Pharmaceuticals	P3	CCC (54)
Sacituzumab Tirumotecan Ovarian Cancer	Merck Sharp & Dohme LLC	P3	CCC (54)
Sacituzumab Tirumotecan Ovarian Neoplasm	Merck Sharp & Dohme LLC	P3	CCC (54)
Sacituzumab Tirumotecan Primary Peritoneal Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (54)
Shr-A2009 Non-Small Cell Lung Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	CCC (54)
Trastuzumab Pamirtecan Breast Cancer	DualityBio Inc.	P3	CCC (54)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Neoplasm	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (54)
rc48-adc Radiotherapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (54)
rc88 Ovarian Carcinoma	RemeGen Co., Ltd.	P2	CCC (54)
rc88 Primary Peritoneal Carcinoma	RemeGen Co., Ltd.	P2	CCC (54)
Trastuzumab Deruxtecan Cancer	Baptist Health South Florida	P2	CCC (54)
Trastuzumab Emtansine Urinary Bladder Carcinoma	Hoffmann-La Roche	P2	CCC (54)
Trastuzumab Emtansine HER2-negative Breast Cancer	University of Chicago	P2	CCC (54)
Trastuzumab Deruxtecan Gastric Cancer	National Cancer Institute (NCI)	P1/2	CCC (54)
Trastuzumab Deruxtecan Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8	National Cancer Institute (NCI)	P1/2	CCC (54)
Trastuzumab Deruxtecan Gastric Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
AEX4089DC1 Anal Neoplasm	MacroGenics	P2	CCC (53)
AEX4089DC1 Androgen-Independent Prostatic Cancer	MacroGenics	P2	CCC (53)
AEX4089DC1 Carcinoma, Squamous Cell of Head and Neck	MacroGenics	P2	CCC (53)
AEX4089DC1 Small Cell Lung Carcinoma	Georgetown University	P2	CCC (53)
AEX4089DC1 Laryngeal Squamous Cell Carcinoma	MacroGenics	P2	CCC (53)
AEX4089DC1 Malignant Melanoma	MacroGenics	P2	CCC (53)
AEX4089DC1 Non-small Cell Carcinoma	MacroGenics	P2	CCC (53)

Showing 276 to 300 of 1,027 assets

PreviousPage 12 of 42Next